Biomerica Secures First Commercial Order for Hp Detect™ from Major European Lab Chain
summarizeSummary
Biomerica Inc. announced its first commercial order for the Hp Detect™ H. pylori diagnostic test from one of Europe's largest clinical laboratory chains, specifically for the UK market. This follows the company's recent MHRA registration for the product in February 2026. For a company that issued a going concern warning in January 2026 due to declining sales and reliance on dilutive financing, this order represents a critical commercial validation and a tangible step towards generating revenue. The high-profile customer could also serve as a reference account, potentially accelerating further distribution agreements across Europe and the US. Traders will be watching for subsequent orders and the financial impact of this new revenue stream on the company's liquidity and future outlook.
At the time of this announcement, BMRA was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $1.87 to $5.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.